IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT06314880 pour Volontaires sains est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'essai clinique NCT06314880 est conçu pour étudier la prevention de Volontaires sains. Il s'agit d'un essai interventionnel en Phase I. Son statut actuel est : en recrutement. L'essai a débuté le 22 juillet 2023 et vise à recruter 300 participants. Dirigé par Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd, l'essai devrait être terminé d'ici le 30 décembre 2024. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 3 avril 2024.
Résumé succinct
The research objective is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity.
Description détaillée
This is a Phase I, single center, randomized, double-blind, placebo-controlled clinical trial conducted in Guangxi Province, China. The purpose of this study is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity. Expected to include 300 subjects, divide them into 5 age groups of 18-50 years old, 6-17 years old, 2-5 years old, 6-23 months old, and 3-5 months old, and 2 dose groups, a total of 10 groups, with 30 people in each group. The experimental group and placebo control group are 20 people and 10 people, respectively.
Titre officiel
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluation the Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli) in a Population Aged 3 Months-50 Years Old
Conditions
Volontaires sainsAutres identifiants de l'essai
- 2022112701
Numéro NCT
Date de début (réel)
2023-07-22
Dernière mise à jour publiée
2024-04-03
Date de fin (estimée)
2024-12-30
Inscription (estimée)
300
Type d'essai
Interventionnel
PHASE
Phase I
Statut
En recrutement
Mots clés
Recombinant Meningococcal Group B Vaccine (E. Coli)
Objectif principal
Prévention
Plan d'attribution
Randomisé
Modèle d'intervention
Parallèle
Masquage
Quadruple aveugle
Bras / Interventions
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
Expérimental18-50 years old 60 people per age group. The first 15 subjects in the 18-50 age group will serve as sentinels, with 10 in the experimental group and 5 in the control group. | Recombinant Meningococcal Group B Vaccine (E. Coli) (Low-dose) Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Recombinant Meningococcal Group B Vaccine (E. Coli) (Hign-dose) Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Contrôle placebo Placebo control. 20 people/group. |
Expérimental6-17 years old 60 people per age group. Divided into high-dose group, low-dose group, and placebo group. | Recombinant Meningococcal Group B Vaccine (E. Coli) (Low-dose) Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Recombinant Meningococcal Group B Vaccine (E. Coli) (Hign-dose) Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Contrôle placebo Placebo control. 20 people/group. |
Expérimental2-5 years old 60 people per age group. Divided into high-dose group, low-dose group, and placebo group. | Recombinant Meningococcal Group B Vaccine (E. Coli) (Low-dose) Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Recombinant Meningococcal Group B Vaccine (E. Coli) (Hign-dose) Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Contrôle placebo Placebo control. 20 people/group. |
Expérimental6-23 months old 60 people per age group. Divided into high-dose group, low-dose group, and placebo group. | Recombinant Meningococcal Group B Vaccine (E. Coli) (Low-dose) Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Recombinant Meningococcal Group B Vaccine (E. Coli) (Hign-dose) Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Contrôle placebo Placebo control. 20 people/group. |
Expérimental3-5 months old 60 people per age group. Divided into high-dose group, low-dose group, and placebo group. | Recombinant Meningococcal Group B Vaccine (E. Coli) (Low-dose) Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Recombinant Meningococcal Group B Vaccine (E. Coli) (Hign-dose) Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group. Contrôle placebo Placebo control. 20 people/group. |
Critère principal d'évaluation
| Critères d'évaluation | Description de critères | Période |
|---|---|---|
The incidence rate of all AEs within 0-30 days after each dose of vaccination | All AEs occurrence within 0-30 days after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination) | within 0-30 days after vaccination |
The incidence rate of solicited AEs within 30 minutes after each dose of vaccination | All solicited AEs occurrence within 30 minutes after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination) | within 30 minutes after vaccination |
The incidence rate of solicited AEs within 0-14 days after each dose of vaccination | All solicited AEs occurrence within 0-14 days after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination) | within 0-14 days vaccination |
The incidence rate of unsolicited AEs within 0-30 days after each dose of vaccination | All unsolicited AEs occurrence within 0-30 days after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination) | within 0-30 days vaccination |
The incidence rate of grade 3 and higher AEs within 0-30 days after each dose of vaccination | All grade 3 and higher AEs occurrence within 0-30 days after each dose of vaccination (occurrences, number of cases, incidence rate, and relationship with vaccination) | within 0-30 days vaccination |
Critères d'éligibilité
Âges éligibles
Enfant, Adulte
Âge minimum
3 Months
Sexes éligibles
Tous
Accepte les volontaires en bonne santé
Oui
- Age range from 3 months to 50 years old, legal guardian and/or individual can provide legal identification;
- The subjects and/or their legal guardians have the ability to understand the research procedures, agree to participate in the study (and/or their legal guardians agree to the child's participation in the study), and sign an informed consent form;
- The subjects and/or their legal guardians are able to participate in all planned follow-up visits;
- On the day of enrollment, the axillary temperature was less than 37.3 ℃;
- Standards for certain groups of people:
- Subjects ≥ 2 years old: laboratory test indicators (as specified in the protocol) within the normal range, or those with abnormalities but no clinical significance (evaluated by clinical doctors);
- Female participants of childbearing age: Agree to take effective contraceptive measures within 6 months from enrollment to full vaccination.
- Have received any Group B meningococcal vaccine in the past;
- A history of invasive diseases caused by meningococcus or gonococci;
- Pregnant or lactating women;
- Have any history of severe allergies to vaccines or drugs in the past, such as allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura;
- Suffering from serious heart disease, liver disease, kidney disease, congenital malformations, developmental disorders, and genetic defects (including but not limited to Down syndrome, moderate to severe thalassemia, etc.) that may interfere with the progress or completion of the study;
- Diagnosed as having congenital or acquired immunodeficiency, or suspected of having serious chronic or systemic diseases that may interfere with the conduct or completion of the study, such as active tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus (HIV), syphilis infection, etc;
- Individuals with encephalopathy, uncontrolled epilepsy, seizures, and other progressive neurological disorders, or a history or family history of mental illness;
- Suffering from contraindications for intramuscular injection such as thrombocytopenia, any coagulation disorders, or receiving anticoagulant therapy;
- Received immunosuppressive therapy within 3 months prior to vaccination, such as continuous use of systemic glucocorticoid therapy for more than 2 weeks, such as prednisone or similar drugs>5mg/day (note: local and inhaled/nebulized steroids can be used);
- Asplenia or splenectomy, functional asplenia caused by any circumstances;
- Subjects with hypertension (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg, suitable for adults);
- Suffering from acute illness or in the acute phase of chronic illness, or using antipyretic, analgesic, and antiallergic drugs (such as acetaminophen, ibuprofen, aspirin, etc.) three days before the first dose of vaccination;
- Within 7 days (≤ 7 days) prior to enrollment, received inactivated vaccines, and within 14 days (≤ 14 days) received live attenuated vaccines;
- Has received blood or blood related products or immunoglobulin (hepatitis B immunoglobulin is acceptable) within 3 months prior to enrollment;
- Premature infants (gestational age<37 weeks), low birth weight infants (birth weight<2500g), and infants with a history of abnormal labor (only applicable to the 3-5 month and 6-23 month age groups);
- Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
- Participating in or planning to participate in clinical trials of other drugs in the near future;
- The researchers believe that there are any conditions in the subjects that may interfere with the evaluation of the research objectives.
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdContact central de l'essai
Contact: Wenjian Fang, +86-18611630252, [email protected]
1 Centres de l'essai dans 1 pays
Guangxi
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, Guangxi, 530028, China
Lirong Huang, Contact, +86-13978620932
En recrutement